Abstract
Purpose Our aim was to quantify the mortality from COVID-19 and identify any interactions with frailty and other demographic factors.
Methods Hospitalised patients aged ≥70 were included, comparing COVID-19 cases with non-COVID-19 controls admitted over the same period. Frailty was prospectively measured and mortality ascertained through linkage with national and local statutory reports.
Results In 217 COVID-19 cases and 160 controls, older age and South Asian ethnicity, though not socioeconomic position, were associated with higher mortality. For frailty, differences in effect size were evident between cases (HR 1.02, 95%CI 0.93-1.12) and controls (HR 1.99, 95%CI 1.46-2.72), with an interaction term (HR 0.51, 95%CI 0.37-0.71) in multivariable models.
Conclusions Our findings suggest that (i) frailty is not a good discriminator of prognosis in COVID-19 and (ii) pathways to mortality may differ in fitter compared with frailer older patients.
Aim To describe associations between frailty, ethnicity, socioeconomic position and mortality in a cohort of older patients presenting to hospital with COVID-19.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
Daniel Davis is funded through a Wellcome Intermediate Clinical Fellowship (WT107467)
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
These analyses were conducted as part of a service evaluation project and individual consent was not necessary as determined by the NHS Health Research Authority.
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
Data available on request
